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Abstract
The interaction of Human Serum Albumin (HSA) with local
anaesthetic, procaine hydrochloride is an important study
from the viewpoint of pharmaceutical sciences to clarify the
structure, function, and properties of HSA-drug complexes.
The investigation has been carried through UV-absorption,
Fluorescence and FTIR spectroscopy. The secondary
structure of the protein and the binding mechanisms of the
drug have been studied using Fourier self-deconvolution
techniques on the obtained IR spectra.
Analysis of UV-absorbance and fluorescence spectra of
procaine-HSA complexes showed a weak binding ability in
quenching the intrinsic fluorescence of HSA by
combinations of static and dynamic quenching procedures.
The binding constant (k) is calculated by graphical analysis
and found to be in the range of (1.115-1.156) × 103 M-1 at
293 K. Spectral analysis of HSA-procaine compound has
revealed a relative decrease in the intensity of the
absorption band of α helix relative to that of β-sheets. This
change in intensity is mainly due to the formation of H-
bonding in procaine-HSA complex.
Keywords: Procaine; HSA; Binding constant; Protein
secondary structure; FT-IR spectroscopy
Introduction
Procaine hydrochloride, 2-(diethyl amino) ethyl p-amino
benzoate has the molecular, formula C13H21 ClN2 O2.HCl, and
its chemical structure is shown in Figure 1 [1]. It is a local
anesthetic drug applied as an injection during surgery or other
medical and dental procedures. It functions as a sodium channel
blocker to ease the pain and it is known to be a short acting
intravenous drug with adverse side effects such as cardiac and
neurological toxicity [2]. Other studies on procaine have shown
it to increase dopamine and serotonin in the brains of animals
[3].
Figure 1: (A) Is the chemical structure of procaine (B) is the chemical structure of HSA.
Human serum albumin (HSA) is composed of three
homologous domains (I - III): I (residues 1-195), II (residues
(196-383) and III (residues 384-585) and each of which is divided
into two subdomains (A and B) and able to bind to a large
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number of ligands at two main binding sites, identified as site I
and site II which are shown in Figure 1B [4-6]. Site I is dominated
by strong hydrophobic interaction with most neutral, bulky,
heterocyclic compounds, while site II is dominated by dipole-
dipole, van der Waals, and/or hydrogen-bonding interactions -
with many aromatic carboxylic acids [7].
HSA is a single monomeric protein formed by 585 amino acids
with 0.6 mM concentration in the blood plasma [8]. HSA has a
dominant role in transporting and arranging various compounds
such as fatty acids, hormones, tryptophan, steroids, metal ions,
therapeutic agents and large number of drugs. HSA is considered
as the major solvable protein components of the circulatory
system, contributing to colloidal oncotic blood its pressure,
binding and transferring poorly soluble drugs in water [9]. A
weak drug binding has a short lifetime which is insufficient to
provide therapeutic effect, whereas a strong binding reduces the
free fraction of drugs with undesirable side effects because of its
slow metabolism and excretion [10-13].
Evaluation of mechanisms of interaction of local anaesthetics
can provide important information about their storage,
transportation, evacuation in the blood makes it possible to
predict their pharmacokinetic and pharmacodynamics
properties such as the degree and duration of anesthetizing
action, the rate of metabolism and/or utilization in peripheral
tissues [14-16].
HSA contains a single intrinsic tryptophan residue (Trp 214) in
domain IIA and its ﬂuorescence is highly sensitive to the ligands
bounded nearby [17-21]. Therefore, it is often used as a probe
to investigate the binding properties of drugs with HSA.
Qualitative analysis of chemical binding to HSA can be
detected by fluorescence spectra. The excitation wavelength,
the emission wavelength, and the fluorescence intensity are the
main three parameters used to study the synthetic information
of the samples. In addition, the curve spectra can also provide
important information. If there is any shift in the excitation or
emission wavelength of the spectra, it could be an indication of
HSA conformational changes [22].
Fluorescence quenching is formed by either dynamic or static
quenching. Dynamic quenching is produced by intermolecular
collision between a quencher and fluorescent molecules at an
excited state, at which effective collision and the quenching
constant should increase with increasing temperature. Usually
dynamic quenching does not affect the structure and bioactivity
of protein. Static quenching is caused by the intramolecular
interaction of quenchers with fluorescent molecules at a ground
state, which forms a new complex with changed structures. In
static quenching, the constancy of new complexes decreases
with the increase in temperature, since high temperatures
contribute to molecular diffusion and the detachment of weakly
bound complexes. Accordingly, dynamic quenching and static
quenching can be distinguished by the impact of temperature
change [23].
A considerable amount of scientific research has proven a
strong connection between band positions of the IR spectra and
changes to the secondary structure of the studied proteins. The
energy associated with the observed absorption bands in several
proteins are linked to certain molecular vibrations in the
secondary structures, such as α helix or β -sheet structures
[23-25]. The vital functions of each protein are dependent on
the three dimensional structures of its components of peptides
and polypeptide.
There are nine IR bands, named amide A, amide B and amides
(I -VII), in the order of decreasing frequency [23,24]. Amide I
band (1600 -1700) cm-1 with its large intensity, is the most useful
for the analysis of the secondary structure of proteins. This band
involves mainly C=O stretching vibration [26,27]. The amide II
band (1480 1600) cm-1 and amide III band (1220-1320) cm-1
contribute greatly to studies despite of the complex nature of
their compositions and can be used for secondary structure
prediction [28-30]. The spectra in the region from about
(1300-500) cm-1 arise due to complicated combinations of (C-C,
C-O, C-N) stretching and bending vibration. This range, referred
to as the fingerprint region, is important because each
compound produces its unique pattern of peaks.
The aim of the present work is to study the interaction
between procaine and HSA. The importance of the study comes
from the fact that procaine shows a short duration of action and
adverse side effects. It is thus highly important for
pharmaceutical sciences to clarify the structure, function, and
properties of HSA- procaine complexes. Therefore, procaine’s
storage and transportation by proteins in the blood plasma
becomes an important issue which requires investigations of the
interaction mechanisms and determining the binding constant
between procaine and HSA. In order to attain these objectives,
UV-Vis absorption spectroscopy, fluorescence spectroscopy and
FTIR spectroscopy were employed to carry out detailed
investigation of procaine-HSA association.
Material and Methods
Materials
HSA (fatty acid free) and Procaine hydrochloride in powder
form, were purchased from Sigma Aldrich chemical company
and were used without any further purifications.
Preparation of stock solutions
HSA was dissolved in phosphate buffered saline (80 mg/ml or
1.2 mM). The concentration of HSA in the buffer solution was
calculated using its listed molecular weight of 66.5 kDa. Procaine
hydrochloride, with the molecular weight of (272.77 g/mol) [28],
was dissolved in double distilled water to prepare the following
concentration (0.6, 0.8, 1.0, 1.2, 2.0, 2.4, and 4.80) mM. In the
final step, each drug solution was added to an equal volume of
the protein solution to attain the desired drug concentrations of
(0.3, 0.4, 0.5, 0.6, 1.0, 1.2 and 2.4) mM. The solutions of
procaine and HSA were incubated for 2 h at 20°C [31] before any
further preparations for spectroscopic measurements.
UV-Vis absorption spectra
The absorption spectra were obtained by the use of a Nano
Drop ND-100 spectrophotometer. The absorption spectra were
recorded for 5 - 10 μL liquid samples of free HSA (40 mg/ml or
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0.6 mM) and for its complexes with procaine solutions with the
following concentrations (0.3, 0.4, 0.5, 0.6, 1.0, 1.2, and 2.4)
mM. Repeated measurements were taken for all the samples
and no significant differences were noticed. The UV-absorption
spectra of procaine-HSA complex are obtained at the
wavelength of 280 nm.
Fluorescence
The following concentrations of procaine-HSA complex (0.3,
0.4, 0.5, 0.6, 1.0, 1.2, and 2.4) mM were prepared for the
fluorescence study. The fluorescence measurements were
performed by a Nano Drop ND-3300 Fluorospectrometer at
25°C. The excitation source comes from one of three solid-state
light emitting diodes (LED's) with excitation source options
include: UV LED with maximum excitation 365 nm, Blue LED
with excitation 470 nm, and white LED from 500 to 650 nm
excitation. A 2048-element CCD array detector covering 400-750
nm, is connected by an optical fibre to the optical measurement
surface. The excitation is performed at the wavelength of 360
nm and the maximum emission wavelength is at 440 nm.
FTIR spectroscopic measurements
The FTIR spectra were measured by a Bruker IFS 66/S
spectrophotometer equipped with a liquid nitrogen-cooled MCT
detector and a KBr beam splitter. The spectrometer was
continuously purged with dry air during the measurements.
Samples in the form of thin films are prepared after 2 h of
incubation of HSA with procaine solution at room temperature,
30 µl of the complex sample were placed on a certain area on a
silicon window plate and left to dry in a closed chamber at room
temperature. The dehydrated films were formed on one side of
a silicon window with different concentrations of procaine
keeping the same protein content in all samples. The obtained
absorption spectra were kept in the range of (400-4000) cm-1.
Each spectrum was obtained by taking the average of 60 scans
to enhance the signal to noise ratio, and the spectral resolution
was at 4 cm-1. The aperture setting remained at 8 mm during all
measurements, because it gave the best signal to noise ratio.
Baseline correction, normalization and peak areas calculations
were done for all the obtained spectra by using OPUS software.
The peak positions were determined using the second derivative
of the spectra and the use of Fourier self-deconvolution
technique. The infrared spectra of HSA and the procaine-HSA
comple were recorded for the region of (1200-1700) cm-1. The
FTIR spectrum of free HSA was acquired by subtracting the
absorption spectrum of the buffer solution from the spectrum of
the protein solution. For the net interaction effect, the
difference spectra {(HSA-procaine)-(HSA)} were generated using
the featureless region of the spectra at (1800-2200 cm)-1 as an
internal standard [27]. The accuracy of this subtraction method
is tested using several control samples with the same protein
and drug concentrations, which resulted in a flat base line
formation as it should.
The obtained spectral differences were used here, to
investigate the nature of the drug-HSA interaction. Silicon
windows (NICODOM Ltd) were used as spectroscopic cell
windows, 30μl of each sample of HSA-procaine at the following
concentrations of (0.15, 0.3, 0.6, 0.7, 0.9) mM was spread on
silicon window using spin coater to obtain equal thickness of
each sample, and then incubator was used to evaporate the
solvent in order to obtain transparent thin film on the silicon
window. All solutions were prepared at the same time at room
temperature and were stored at the same closed chamber.
Results
UV-Vis absorption spectroscopy
UV-Vis absorption spectroscopy is one of the most common
and effective experimental techniques used in calculating
binding constants for several drug-protein complexes [32-34]. A
complex has formed by the interaction of procaine with HSA as
shown from the absorption spectra in Figure 2. The intensity of
UV absorption of HSA increased with increasing concentrations
of procaine indicating formation of procaine-HSA complex. A
small red shift of the absorption peak at 280 is noticed with the
increase of procaine concentration most likely due to the
complex formation of procaine with HSA.
Figure 2: UV-Absorbance spectra of Procaine-HSA complexes
at these concentration
(a= Procaine, b= HSA, c=0.3 mM, d=0.4-mM, e=0.5 mM,
f=0.6 mM, g=1 mM, h=1.2 mM, i =2.4 mM)
Procaine + HSA ↔ Procaine: HSA (1)� = ��������:����������� ��� (2)
The absorption data were treated using linear reciprocal plots
based on the following equation [35].1� − �0 = 1�∞− �0 + 1�∞− �0 �   . 1� (3)
Where A0 corresponds to the initial absorption of protein at
280 nm in the absence of ligand, A∞ is the final absorption of
the ligated protein, and A is the recorded absorption at different
procaine concentrations (L). The double reciprocal plot of 1/(A-
A0) versus 1/L is linear (Figure 3) and the binding constant (K)
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can be calculated from the ratio of the intercept to the slope,
which is found to be 1.115 × 103 M-1. This binding constant
value shows a relatively weak procaine-HSA interaction in
comparison to other drug-HSA complexes with binding constants
in the range of 105 and 106 M-1 [35-37]. The reason for the
weak formation can be attributed to the presence of mainly
hydrogen-bonding interaction between protein donor atoms
and the procaine polar groups or an indirect drug-protein
interaction through water molecules [38].
Figure 3: The plot of 1/ (A-A0) vs. 1/L for HSA with different
concentration of procaine
Fluorescence Spectroscopy
Fluorescence quenching refers to any mechanism which
reduces the fluorescence intensity of a fluorophore.
Fluorescence quenching of HSA results from the tryptophan,
tyrosine, and phenylalanine residues. The intrinsic fluorescence
of HSA is almost due to the contribution of tryptophan alone,
because phenylalanine has very low quantum yield and the
fluorescence of tyrosine is almost totally quenched if it is ionized
or near an amino group, a carboxyl group, or a tryptophan
residue [22]. However, in fluorescence spectra studies on
protein- drug interactions, the fluorescence intensity of proteins
are usually sensitive to interference by ligands or newly
produced complexes which exhibit significant fluorescence at or
near the chosen excitation or emission wavelengths [39]. The
ligand-binding process during protein-ligand complex is mainly
governed by four types of weak, noncovalent forces including
hydrogen bond, van der Waals force, electrostatic, and
hydrophobic interactions [40].
When HSA is excited at 280 nm, it emits strong intrinsic
fluorescence at 440 nm which is shown in Figure 4. This
phenomenon is due to Trp residue located at the 214th position
of the chain and the Try residues in HAS [41,42]. Further, the
fluorescence intensity of HSA decreases due to the increase of
procaine concentration, while the peak position shows little or
no change at all.
The intrinsic fluorescence of HSA is highly sensitive to any
slight changes in the local environment of HSA, and becomes
obviously weakened by the following factors such as protein
conformational transition, bio-molecule binding, and
denaturation [43].
Figure 4: Fluorescence emission spectra of HSA in the
presence of various concentration of procaine (a=free
procaine 4.8 Mm, b=2.4 mM, c=1.2 mM, d=1.0 mM, e=0.6
mM, f=0.5 mM, g=0.4 mM, h= 0.3 mM, i=free HSA)
The mechanisms of fluorescence quenching are either
dynamic quenching or static quenching. Dynamic and static
quenching are caused by different means, namely diffusion for
dynamic quenching and ground state complex formation for
static quenching [38]. In addition, it is known that higher
temperatures increase diffusion coefficients leading to an
increase in dynamic quenching constants. In contrast, the rise of
temperature can decrease the stability of a complex which leads
to a decrease in the static quenching constant.
In order to confirm the nature of the quenching mechanism,
the fluorescence quenching can be analyzed by the Stern-
Volmer equation [44]�0� = 1 + ��0 � = 1 + ��� � (4)
Where F and F0 are the ﬂuorescence intensities with and
without quencher, kq is the quenching rate constant of the
biomolecule, Ksv is the Stern Volmer quenching constant, (L) is
the concentration of procaine, and τ0 is the average life time of
the molecule without quencher 10-8 s.
The value of Ksv (0.00566 × 103 Mol-1) is equal to the slope of
a best fit straight-line analysis as shown in Figure 5. The
quenching rate constant Kq, can be calculated using the
ﬂuorescence life time of 10-8 s for HSA [45]. The obtained value
for K is 5.66 × 108 Mol-1 s-1, which is two orders of magnitude
smaller than the maximum scatter collision quenching constant
for various quenchers with biopolymer 2×1010 Mol-1 s-1 [46].
This indicates that procaine has low binding affinity with HSA,
and the binding is weak and can be easily reversed. Other low
binding constants within similar range of 103 Mol-1 have also
been reported [47]. Usually, low binding to HSA results in a
shorter life time or poorer distribution of drugs in the plasma,
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whereas the strong binding reduces the levels of free plasma
[48]. Therefore, the binding is weak and can be attributed to
combinations of static and dynamic quenching, Lineweaver-Burk
equation, is used [49,50]1�0− � = 1�0 + 1���0 (5)
Where K is the static quenching constant with the unit of L
mol-1, which describes the binding efficiency of micro molecules
to biological macromolecules at ground state [51]. The value of K
can be determined from the slope and the intercept in Figure 6.
The value of K is 1.156 × 103 Mol-1, which agrees well with the
value obtained earlier by UV spectroscopy. The weak quenching
constant in this case has led to a lower value of binding constant
between the drug and HSA due to an effective hydrogen
bonding between procaine and HSA. The interaction of procaine
molecules with HSA is initiated by electrostatic forces, but
subsequently the hydrophobic interactions play the major role in
procaine-HSA interactions. The low value of the binding constant
showed that procaine quenched the intrinsic fluorescence of
HSA through dynamic quenching mechanism. Furthermore,
hydrophobic interaction played a major role in the binding
process. Using fluorescence and UV absorption spectroscopy
showed that procaine induces protein structural changes. The
red shift in Figure 2, and the good linearity in the Stern-Volmer
equation imply the role of static quenching by procaine [52].
Figure 5: The Stern-Volmer plot for procaine -HSA complexes
Figure 6: The plot of 1/(F0 - F) vs. 1/[L(10)-3]
FTIR Spectroscopy
The absorption spectra of HSA free and HSA-procaine complex
are presented in Figure 7 showing the major amide bands (I, II,
III) and the fingerprint region. All major peaks have been
identified by taking the second derivative of the spectra and by
applying Fourier self-deconvolutions (FSD) to the spectra as
shown in Figure 8.
Figure 7: Spectra of HSA free (A) and Procaine-HSA complex
0.9 mM (B)
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Figure 8: FSD Spectra of (A) HSA free and (B) HSA-Procaine
complex 0.6 mM
The peak positions for the spectra of the protein and its
complex with procaine are listed in Table 1. Infrared spectra of
proteins exhibit a number of amide bands, which represent
different vibrations of the peptide moiety. The FSD analysis of
the absorption spectra for HSA in the amide I region (1600
-1700) cm-1 reveals the separate components of the band. The
peaks of these bands correspond to the C-O stretching
vibrations of the amide I group, coupled to the C-N stretching
and C-C-N deformation mode [51]. The individual components
of amide II (1600-1480) cm-1 are mainly due to out of phase
combination of N- H in-plane bending and C-N stretching
vibration modes [53]. As for amide III (1220=1320) cm-1, the
absorption bands are caused by in-phase combination of the N-
H bending and the C-N stretching vibration with some
contributions from the C-O in-plane bending and the C-C
stretching vibration [53,54].
The component bands of amide I were attributed according to
the well-established assignment criterion [55,56]. The bands
range (1615-1637) cm-1 and (1680-1700) cm-1 are generally
assigned to β-sheets, (1638-1648) cm-1 are assigned to random
coil, (1649 -1660) cm-1 to α -helix and (1660-1680) cm-1 to β-
turn structure. The amide II components are assigned in the
following order (1488-1504) and (1585-1600) cm-1 to β=sheets,
(1504-1527) cm-1 to random coil, (1527 -1560) cm-1 to α- helix
and (1564-1585) cm-1 to turn structure [57]. The component
bands of Amide III have been assigned as follows: α-helix
(1330-1290) cm-1, β-turn (1290-1270) cm-1, random coil
(1270-1250) cm-1 and β-sheets (1250-1220) cm-1[56].
The peak positions of amide I bands in HSA spectrum stayed
about the same as shown in Table 1. The only noticeable change
is the disappearance of the small peak at 1612 cm-1 and the rise
of a new peak at 1602 cm-1 with higher concentration of
procaine. The amide II bands did not show any major changes in
their peak positions with the different concentrations of HSA-
Procaine complexes. As for amide III, the following peaks (1310,
1294, 1243, and 1224) cm-1 maintain their positions, while the
two weak bands at 1277 and 1243 cm-1 have been over
shadowed by a new peak at 1273 cm-1. The two new peaks at
1602 and 1273 cm-1 are due to C=C (aromatic) stretching mode
and C-O and C-N stretching mode of procaine, respectively
[58-60]. Their dominant effect appears to be due to the
presence of unbound procaine molecules within the HSA-
procaine complex which is related to the weak binding constant
between procaine and HSA.
Table 1: Absorption peak positions in Wave numbers (cm-1) for Procaine-HSA at different concentrations.
Bands Range (cm-1) Free HSA concentrations
Amide I 1700-1600 0 0.15 mM 0.3 mM 0.6 mM 0.7 mM 0.9 mM
Β-sheets  ---- ----- 1603 1603 1603 1603
  1613 1612 -- -- -- --
 β-sheets 1627 1628 1626 1626 1626 1627
 Random 1640 1641 1640 1640 1641 1641
 α-helix 1657 1658 1658 1657 1659 1659
 Turns 1679 1678 1678 1679 1679 1679
 β-sheets 1694 1694 1694 1694 1694 1694
Amide II 1600-1480       
 β-sheets 1498 1498 1498 1498 1498 1498
 β-sheets 1515 1516 1515 1515 1516 1516
 Random 1532 1532 1532 1532 1532 1532
 α-helix 1549 1549 1549 1549 1549 1549
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 Turn 1569 1569 1569 1569 1569 1569
 β-sheets 1585 1585 1585 1584 1584 1584
Amide III 1320-1220       
 β-sheets 1224 1224 1224 1224 1224 1224
 β-sheets 1244 1244 1244 1244 1244 1244
 Random 1267 1267     
    1273 1273 1273 1273
 Random 1277 1277     
 Turns 1295 1295 1295 1295 1295 1295
 α-helix 1309 1309 1309 1310 1310 1310
The relative intensities of all component bands of amide I,
amide II, and amide III were calculated and listed in Table 2. The
following bands showed major increase in their intensities with
increasing procaine concentration in the complex (1603, 1309,
and 1273) cm-1, while these bands (1627, 1548) cm-1 showed
very small increase in their relative intensities. On the other
hand, the following bands (1657, 1531, and 1294) cm-1 show
little or no decrease in their intensities. The bands at (1613,
1277, and 1266) cm-1 disappeared due to overlapping by
neighboring bands and the rest of the bands showed no change
in their intensities.
Table 2: Relative intensity of absorption bands for Procaine-HSA at different concentrations.
Bands Range (cm-1) Intensity % Intensity % Intensity % Intensity % Intensity % Intensity %
Amide I 1700-1600 0 0.15 mM 0.3mM 0.6mM 0.7mM 0.9mM
        
β-sheets 1606-1620 3 5     
β-sheets 1620-1633 5 7 7 9 17 14
Random 1633-1647 8 8 9 9 10 8
α-helix 1649-1670 46 40 40 46 25 39
Turns 1672-1686 18 19 20 18 21 18
β-sheets 1687-1700 20 21 24 18 26 21
        
Amide II 1600-1480       
        
β-sheets 1487 1506 12 12 13 13 14 14
β-sheets 1506-1523 14 13 13 14 11 13
Random 1523-1539 11 15 11 10 10 9
α-helix 1541- 1558 23 25 23 25 20 24
Turns 1560-1585 19 19 19 20 21 21
β-sheets 1585-1600 21 16 21 18 24 19
        
Amide III 1320-1220       
        
β-sheets 1222-1256 51 41 42 34 30 29
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Random 1259-1287 15 21 30 40 43 45
Turns 1288-1302 5 6 5 5 5 5
α-helix 1302-1319 29 32 23 21 22 21
The difference in FSD spectra [(HSA+ procaine)-(HSA)] were
obtained to investigate the intensity variations and the results
are shown in Figure 9. The strong negative features at 1601 and
1277 cm-1 were due to absorbance by free procaine. While the
band at 1309 cm-1 formed by double contributions from free
procaine and procaine-HSA complex. The positive peaks shown
at 1657 and 1554 cm-1 represent the decrease in intensity of the
α-helix bands of the amide I and amide II respectively. This
decrease is attributed to the unfolding of the protein in the
presence of procaine as a result of the H-bonding formation
with protein C=O and C-N groups [61]. As for any possible
changes in the intensity of α-helix in the amide III region, it could
not be determined due to the overlapping by the procaine band
at 1309 cm-1. In general these changes of the peak positions,
intensities and peak shapes are considered to be overwhelming
evidences of secondary structure changes have occurred as a
result of procaine interaction with HSA.
Figure 9: Top Part shows HSA spectra (B) and HSA-procaine
0.6 mM (A). Bottom part shows the difference Spectra
between (HSA-procaine complex) - (free HSA).
Conclusions
In this paper, the interaction between procaine and HSA was
investigated by fluorescence spectroscopy, UV-Vis absorption
and FTIR spectroscopy. The results indicate that the fluorescence
quenching mechanism of HSA by Procaine binding indicate
contributions from both a static and dynamic quenching
process. The binding reaction of procaine with HSA showed a
binding constant is in the range of (1.115-1.156) × 103 M-1. The
experimental results pointed to contributions from different
interaction mechanisms between procaine and HSA. It seems
that, the complexation of procaine molecules with HSA is
initiated by electrostatic forces, but subsequently the
hydrophobic interaction played a major role in this
complexation.
The infrared spectroscopic results show that drug- protein
binding occurs with the participation of the tryptophan residues
and some conformation of the protein secondary structure. The
variations in the relative intensities of the absorption bands
showed a slight decrease in α-helical contents and a minor
increase in β-sheet contents.
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